Jonathon Vallejo
Overview
Explore the profile of Jonathon Vallejo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woods A, Norsworthy K, Choe M, Gehrke B, Chen H, Vallejo J, et al.
Clin Cancer Res
. 2024 Oct;
31(1):12-17.
PMID: 39475462
On December 1, 2022, the FDA approved the new molecular entity olutasidenib (Rezlidhia, Rigel Pharmaceuticals), a small-molecule inhibitor of isocitrate dehydrogenase 1, for the treatment of adult patients with relapsed...
2.
Pamuk G, Chow E, Ionan A, Chen H, Lee S, Hsu V, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4266-4271.
PMID: 39088257
On October 29, 2021, FDA granted accelerated approval to asciminib (SCEMBLIX; Novartis), a tyrosine kinase inhibitor (TKI), for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukemia...
3.
Rodriguez L, Gormley N, Lu R, Amatya A, Demetri G, Flaherty K, et al.
Clin Cancer Res
. 2024 Jul;
30(18):3974-3982.
PMID: 39037364
Advances in anticancer therapies have provided crucial benefits for millions of patients who are living long and fulfilling lives. Although these successes should be celebrated, there is certainly room to...
4.
Vallejo J, Singh H, Larkins E, Drezner N, Ricciuti B, Mishra-Kalyani P, et al.
Oncologist
. 2024 Feb;
29(5):422-430.
PMID: 38349736
Background: Programmed death ligand 1 (PD-L1) expression is recognized as a key biomarker in the treatment of non-small cell lung cancer (NSCLC) with anti-PD(L)1 inhibitors. Previous work has highlighted that...
5.
Woods A, Norsworthy K, Wang X, Vallejo J, Chow E, Li R, et al.
Clin Cancer Res
. 2023 Nov;
30(7):1226-1231.
PMID: 38010220
On May 25, 2022, FDA approved a supplemental application for ivosidenib (Tibsovo; Servier) extending the indication in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in older adults or...
6.
Yang P, Zhao Y, Nie L, Vallejo J, Yuan Y
Biometrics
. 2023 Sep;
79(4):2857-2868.
PMID: 37721513
Mixture priors provide an intuitive way to incorporate historical data while accounting for potential prior-data conflict by combining an informative prior with a noninformative prior. However, prespecifying the mixing weight...
7.
Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, et al.
J Clin Oncol
. 2022 Sep;
40(30):3489-3500.
PMID: 36095296
This review highlights strategies to integrate dose optimization into premarketing drug development and discusses the underlying statistical principles. Poor dose optimization can have negative consequences for patients, most commonly because...
8.
Pulte E, Chen H, Price L, Gudi R, Li H, Okusanya O, et al.
Oncologist
. 2022 May;
27(2):149-157.
PMID: 35641211
On December 18, 2020, US Food and Drug Administration (FDA) approved a supplemental application for ponatinib extending the indication in patients with chronic-phase chronic myeloid leukemia (CP-CML) to patients with...
9.
Kim N, Norsworthy K, Subramaniam S, Chen H, Manning M, Kitabi E, et al.
Clin Cancer Res
. 2022 Apr;
28(16):3411-3416.
PMID: 35435961
On July 7, 2020, the Food and Drug Administration approved Inqovi (Otsuka Pharmaceutical Co.), an oral fixed-dose combination tablet comprising 35 mg decitabine, a hypomethylating agent, and 100 mg cedazuridine,...
10.
Le R, Wang X, Zhang H, Li H, Przepiorka D, Vallejo J, et al.
Oncologist
. 2022 Apr;
27(6):493-500.
PMID: 35363318
On September 22, 2021, the Food and Drug Administration approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) after the failure of one or two lines of systemic therapy...